Ixaltis
Latest round
- Series A
Last raised
- Dec 2018
Total raised
- $9M
Investors
- 4
About Ixaltis
Founded in 2012 in Toulouse, France, Ixaltis SA specializes in pharmaceutical development, particularly for genitourinary and renal conditions. The CEO is Roberto Gradnik. Ixaltis specializes in the development of innovative pharmaceutical products targeting genitourinary and renal diseases. The company's core product offering includes Litoxetine (IXA-001), developed to address unmet medical needs in treating disorders of the urogenital tract. Additionally, Ixaltis is advancing two other compounds, IXA-002 and IXA-003, aimed at related indications, catering to healthcare providers and institutions involved in urology and renal care.9 mn, reflecting its transactional structure that likely includes partnerships with healthcare providers and pharmaceutical wholesalers for its products. The revenue model may involve licensing agreements for the development and distribution of its compounds, including Litoxetine. The company is also exploring opportunities for expansion into new markets and regions, aiming to establish partnerships and collaborations with healthcare institutions globally.
Who invested in Ixaltis
4 investors across 3 rounds
See all investors in Ixaltis
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Ixaltis
Who invested in Ixaltis?
Ixaltis has 4 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Ixaltis raised?
Ixaltis has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Ixaltis last raise money?
Ixaltis's most recent round on record is a Series A, in Dec 2018.
What does Ixaltis do?
Founded in 2012 in Toulouse, France, Ixaltis SA specializes in pharmaceutical development, particularly for genitourinary and renal conditions.
Where is Ixaltis headquartered?
Ixaltis is headquartered in Toulouse, France.
Which VCs invest in companies like Ixaltis?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Highland Europe back pharmaceuticals companies at Ixaltis's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series A
Raising like Ixaltis? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.